Advertisement

Topics

GSK Ships 2017-18 Seasonal Influenza Vaccines for U.S. Market

10:28 EDT 17 Jul 2017 | PharmPro

GSK expects to supply up to 40 million doses for the U.S. market in the 2017-18 season. The quadrivalent vaccines are designed to help protect against two main types of flu viruses, A and B, which can cause mild to severe illness.
Contributed Author: 
Topics: 

Original Article: GSK Ships 2017-18 Seasonal Influenza Vaccines for U.S. Market

NEXT ARTICLE

More From BioPortfolio on "GSK Ships 2017-18 Seasonal Influenza Vaccines for U.S. Market"

Quick Search
Advertisement
 

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...